Addex Therapeutics Ltd (ADXN) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN...

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update

● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Addex Convenes Annual General Meeting 2024

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN...

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...

Addex to Present at Bio€quity Europe 2024

Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical...

Addex Provides Update on ADX71149 Phase 2 Epilepsy Study

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and...

Addex to Present at the Swiss Biotech Day 2024

Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive...

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Addex receives CHF5M and 20% share of Neurosterix  Perceptive Advisors leads $63M investment into Neurosterix ...